BJMO - volume 16, issue 8, december 2022
L. Croes PhD, T. Feys MBA, MSc, C. Vulsteke MD, PhD
The 2022 annual meeting of the European Society of Medical Oncology (ESMO) was a grand cru when it comes to ovarian cancer, with the presentation of long-term data of several pivotal studies evaluating firstline maintenance therapy with a PARP inhibitor. Also, in the recurrent ovarian cancer setting, there was some interesting PARP news. In addition to this, ESMO featured the presentation of multiple studies evaluating checkpoint inhibitors in the management of ovarian cancer, endometrium and cervical cancer.
(Belg J Med Oncol 2022;16(8):380–6)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
